Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
2.171
-0.019 (-0.89%)
Nov 22, 2024, 4:00 PM EST - Market closed
Senti Biosciences Employees
Senti Biosciences had 48 employees as of December 31, 2023. The number of employees decreased by 74 or -60.66% compared to the previous year.
Employees
48
Change (1Y)
-74
Growth (1Y)
-60.66%
Revenue / Employee
n/a
Profits / Employee
-$1,477,000
Market Cap
9.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 48 | -74 | -60.66% |
| Dec 31, 2022 | 122 | 33 | 37.08% |
| Dec 31, 2021 | 89 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Star Equity Holdings | 171 |
| T2 Biosystems | 113 |
| BiomX | 71 |
| Eyenovia | 57 |
| Imunon | 33 |
| Dominari Holdings | 28 |
| Kiora Pharmaceuticals | 12 |
| BioRestorative Therapies | 11 |
SNTI News
- 8 days ago - Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights - GlobeNewsWire
- 2 months ago - Senti Bio to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights - GlobeNewsWire
- 3 months ago - Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202 - GlobeNewsWire
- 4 months ago - Senti Bio Announces Reverse Stock Split - GlobeNewsWire
- 5 months ago - Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy - GlobeNewsWire
- 6 months ago - Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia - GlobeNewsWire
- 7 months ago - Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights - GlobeNewsWire